The management of latent tuberculosis infection in Romania – limits and perspectives

Autor: Gina Ciolan, Bucureşti Universitatea de Medicină şi Farmacie „Carol Davila', Mihaela Tănăsescu, Constantin Marica, Bucureşt Institutul de Pneumoftiziologie „Marius Nasta', Mara Bălteanu
Rok vydání: 2015
Předmět:
Zdroj: Romanian Journal of Medical Practice. 10:226-233
ISSN: 2069-6108
1842-8258
DOI: 10.37897/rjmp.2015.3.2
Popis: In 2014 the World Health Organization adopted a new strategy for tuberculosis control – infectious disease with the highest mortality in the world after AIDS. This new strategy – The End TB Strategy – is aimed to reducing tuberculosis disease by 90% and tuberculosis mortality by 95%, so that by 2035 TB is no longer considered a problem global public health. The World Health Organization report on tuberculosis published in 2014 is estimated that about one third of the world population is infected with M. tuberculosis (approx. 2 billion); 5-10% of them will develop active disease, thus fullfiling the TB pandemia. It is therefore an essential objective to diagnose these cases of latent tuberculosis infection and to establish precise criteria of the latent TB infection treatment. Tuberculin skin test is the most important test for emphasis of TB infection in an organism. The results obtained in recent years in mycobacterial genomics and human cell immunology have led to the development of other tests that detect tuberculosis infection, of which the most commonly used is the test that measures the release of IFN-γ (Interferon gamma-releasing assay IGRA). Any patient with increased risk of infection to disease progression and who has a positive skin test is a candidate for treatment. Immuno-compromised patients (HIV infected, treatment with anti-TNF, organ transplantation, immunosuppressive medication) with LTBI have a higher risk of reactivation. Immuno-compromised patients with LTBI should receive treatment.
Databáze: OpenAIRE
Externí odkaz: